Earnings & Targets in Focus for Medtronic, Inc. (NYSE:MDT), Hologic, Inc. (NASDAQ:HOLX)

For the current quarter, analysts are expecting Medtronic, Inc. (NYSE:MDT) to report EPS of $N/A. This consensus estimate is provided by Zacks Research. After the period that ended on N/A, Medtronic, Inc. (NYSE:MDT) reported an EPS actual of $N/A. The difference between the actual and estimate resulted in a surprise factor of N/A%. The company is expected to release their next earnings report on or around N/A. Interested parties will be watching to see how company results compare to what the Street was projecting for the fiscal period.

Shares of Medtronic, Inc. (NYSE:MDT) have a current ABR or average broker rating of N/A. This consensus recommendation is also provided by Zacks Research. The recommendation falls on a scale between 1 and 5. A broker rating of 1 would translate into a Strong Buy. A rating of 5 would indicate a Strong Sell recommendation. This consensus broker rating may help shed some light on how the sell-side is currently viewing company stock.

Covering analysts often provide target price projections for company shares. The current Zacks consensus target price on shares of Medtronic, Inc. (NYSE:MDT) is $N/A. The top analyst target is $N/A, and the lowest target is $N/A on the stock. Because of the different techniques used to gauge a company target price, estimates may be quite different from one analyst to another.

For the current quarter, analysts are expecting Hologic, Inc. (NASDAQ:HOLX) to report EPS of $N/A. This consensus estimate is provided by Zacks Research. After the period that ended on N/A, Hologic, Inc. (NASDAQ:HOLX) reported an EPS actual of $N/A. The difference between the actual and estimate resulted in a surprise factor of N/A%. The company is expected to release their next earnings report on or around N/A. Interested parties will be watching to see how company results compare to what the Street was projecting for the fiscal period.

Shares of Hologic, Inc. (NASDAQ:HOLX) have a current ABR or average broker rating of N/A. This consensus recommendation is also provided by Zacks Research. The recommendation falls on a scale between 1 and 5. A broker rating of 1 would translate into a Strong Buy. A rating of 5 would indicate a Strong Sell recommendation. This consensus broker rating may help shed some light on how the sell-side is currently viewing company stock.

Covering analysts often provide target price projections for company shares. The current Zacks consensus target price on shares of Hologic, Inc. (NASDAQ:HOLX) is $N/A. The top analyst target is $N/A, and the lowest target is $N/A on the stock. Because of the different techniques used to gauge a company target price, estimates may be quite different from one analyst to another.

Leave a Comment